Triazolam-13C2-d4 (CRM)

Triazolam-13C2-d4 (CRM) (Cay-42201) is intended for use as an internal standard for the quantification of triazolam (Cay-39683, Cay-22577) by GC- or LC-MS. Triazolam is categorized as a benzodiazepine. It substitutes for cocaine (Cay-ISO60176, Cay-16186, Cay-22165) in baboons. Formulations containing triazolam have been used in the treatment of insomnia. Triazolam-13C2-d4 is regulated as a Schedule IV compound in the United States. Triazolam-13C2-d4 (CRM) (Cay-42201) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.Formal Name: 8-chloro-6-(2-chlorophenyl-3,4,5,6-d4)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-13C2. Molecular Formula: C15[13C]2H8Cl2D4N4. Formula Weight: 349.2. Formulation: (Request formulation change), A 100 mg/ml solution in methanol. SMILES: ClC1=CC=C2C(C(C3=C([2H])C([2H])=C([2H])C([2H])=C3Cl)=N[13CH2][13C]4=NN=C(C)N42)=C1. InChi Code: InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3/i2D,3D,4D,5D,9+1,16+1. InChi Key: JOFWLTCLBGQGBO-TWJZHOEHSA-N.